ABSTRACT
Twenty-one patients suffering from the premenstrual syndrome were each studied during three menstrual cycles. After a control cycle, bromocriptine and placebo were given during the luteal phase of the cycle in a random double-blind cross-over manner, each patient serving as her own control. The dosage of bromocriptine was 2-5 mg twice daily. Serum prolactin levels were found to equal during the follicular and luteal phases, except when reduced by bromocriptine. Serum progesterone and oestradiol-17-beta were within normal ranges, and did not change during treatment. Medication considerably improved all the premenstrual symptoms, but mastodynia was the only one where bromocriptine was significantly better than the placebo.
Subject(s)
Bromocriptine/therapeutic use , Ergolines/therapeutic use , Premenstrual Syndrome/drug therapy , Adolescent , Adult , Clinical Trials as Topic , Double-Blind Method , Estradiol/blood , Female , Humans , Middle Aged , Premenstrual Syndrome/blood , Progesterone/blood , Prolactin/bloodSubject(s)
Prenatal Diagnosis , Abortion, Spontaneous , Adult , Amniocentesis , Diagnostic Errors , Female , Humans , Male , Pregnancy , Time Factors , UltrasonicsABSTRACT
The renal lithium clearance of a manic-depressive woman rose when she became pregnant and fell to the prepregnancy level when she gave birth. The lithium clearances of four healthy women were higher during pregnancy than after delivery. This emphasizes the need for frequent determinations of the serum lithium concentration and appropriate dosage adjustments during pregnancy and delivery.
